ROPN1 inhibitors belong to a class of chemical compounds that modulate the function of the ROPN1 (Ropporin 1A) protein. ROPN1 is a protein found in various cell types, playing pivotal roles in cellular processes that are not fully elucidated but are believed to involve the regulation of cell signaling, particularly in cilia and flagella. It's important to understand that the structure and function of proteins like ROPN1 can be influenced by various molecules, and inhibitors are specifically designed or identified to reduce or block the function of their target protein.
Chemically, ROPN1 inhibitors can be of diverse structures, often dependent on the specific site of the ROPN1 protein they target. The molecular interaction between an inhibitor and ROPN1 can be due to various types of chemical bonds, including hydrogen bonds, van der Waals forces, ionic bonds, and covalent bonds. The specificity and affinity of an inhibitor for ROPN1 largely determine its potency. It's also worth noting that the development of ROPN1 inhibitors, like other types of inhibitors, involves a rigorous process of chemical synthesis and biological evaluation. Computational tools, crystallography, and various biochemical assays are employed to understand the binding mechanism, validate the inhibitory effect, and ensure specificity towards ROPN1 without affecting other unrelated cellular processes. As with any chemical class, the safety, solubility, and stability of these compounds are of paramount importance and are evaluated extensively during the development and characterization stages.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Zanubrutinib | 1691249-45-2 | sc-507434 | 5 mg | $360.00 | ||
Binds irreversibly to the cysteine-481 residue of Bruton's tyrosine kinase, inhibiting B-cell receptor signaling in B-cell malignancies. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
Selectively inhibits B-cell lymphoma-2 (BCL-2) to promote apoptosis in cancer cells, particularly effective in chronic lymphocytic leukemia (CLL). | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Covalently binds to the cysteine-481 residue of Bruton's tyrosine kinase (BTK), disrupting B-cell receptor signaling in B-cell malignancies. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $240.00 $1030.00 | 7 | |
Competitively inhibits androgen receptor (AR) signaling by binding to AR and blocking its activation, used in prostate cancer therapy. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Inhibits the tyrosine kinase activity of BCR-ABL fusion protein in chronic myeloid leukemia (CML) cells, blocking the proliferation of leukemic cells. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Targets the epidermal growth factor receptor (EGFR) tyrosine kinase, hindering cell growth in EGFR-mutated lung cancer by inhibiting downstream signaling pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inhibits multiple kinases, including RAF kinases and VEGFR, to block angiogenesis and cell proliferation in various cancer types, particularly hepatocellular carcinoma. | ||||||
Rucaparib | 283173-50-2 | sc-507419 | 5 mg | $150.00 | ||
PARP inhibitor that disrupts DNA repair in BRCA-mutated cancer cells, leading to genomic instability and cell death. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
PARP inhibitor that interferes with DNA repair mechanisms in BRCA-mutated tumor cells, causing synthetic lethality and apoptosis. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Cyclin-dependent kinase (CDK) 4/6 inhibitor, halting cell cycle progression in hormone receptor-positive breast cancer by blocking the phosphorylation of retinoblastoma protein. | ||||||